

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gil Ben-Menachem et al.

Application No.: To be assigned

Filed: To be assigned

Confirmation No.: To be assigned

For: CHOLESTEROL-CONTAINING
COMPOUNDS AND THEIR USE AS
IMMUNOGENS AGAINST BORRELIA
BURGDORFERI

Examiner: To be assigned

Art Unit: To be assigned

Attorney Reference No. 4239-68220-03

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV669611326US in an envelope addressed to: MAIL STOP PCT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s)

Nayak P. Pappas

Date Mailed September 27, 2005

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.


Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

JC12 Rec'd PCT/PTC 27 SEP 2005

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Wayne W. Rupert
Registration No. 34,420

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-68220-03
	Application Number	To be assigned
	Filing Date	To be assigned
	First Named Inventor	Gil Ben-Menachem
	Art Unit	To be assigned
	Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		4,189,471	19 Feb 1980	Ponpipom et al.
		4,229,441	21 Oct 1980	Ponpipom et al.
		4,721,617	26 Jan 1988	Johnson
		6,203,798	20 Mar 2001	Bergstrom et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		Europe	EP 0 023 865 A2	11 Feb 1981	Merck & Co. Inc.

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Ben-Menachem et al., "A newly discovered cholesteryl galactoside from <i>Borrelia burgdorferi</i> ," PNAS 100(13):7913-7918, June 2003
		Cinco et al., "Evidence for (lipo) oligosaccharides in <i>Borrelia burgdorferi</i> and their serological specificity," <i>FEMS Microbiology Immunology</i> 76:33-38, 1991
		Eiffert et al., "Identification of an immunoreactive non-proteinaceous component in <i>Borrelia burgdorferi</i> ," <i>Med Microbiol Immunol</i> 180:229-237, 1991
		Hossain et al., "Structural analysis of glycolipids from <i>Borrelia burgdorferi</i> ," <i>Biochimie</i> 83:683-692, 2001
		Schröder et al., "Acylated Cholesteryl Galactoside as a Novel Immunogenic Motif in <i>Borrelia burgdorferi Sensu Stricto</i> ," <i>The Journal of Biological Chemistry</i> 278(36):33645-33653 (published electronically June 2003)
		Wheeler et al., "Nonprotein Antigens of <i>Borrelia burgdorferi</i> ," <i>The Journal of Infectious Diseases</i> , 167:665-674, 1993
		International Search Report, International Publication No. WO 2004/089969 A3, published October 21, 2004

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	